Burland W L, Duncan W A, Hesselbo T, Mills J G, Sharpe P C, Haggie S J, Wyllie J H
Br J Clin Pharmacol. 1975 Dec;2(6):481-6. doi: 10.1111/j.1365-2125.1975.tb00564.x.
Cimetidine, a new H2-receptor antagonist, was safely administered to eighteen healthy man by the intravenous, intraduodenal or oral route. 2 When gastric secretion was maximally stimulated by either histamine or pentagastrin, the simultaneous administration of cimetidine produced marked inhibition of both acid and pepsin secretion. 3 Cimetidine was well absorbed by mouth and had a blood half-life of 2 hours. 4 Cimetidine was rapidly excreted via the kidneys and about 70% of the excreted material was unchanged drug. 5 Clinical evaluation of cimetidine in patients with peptic ulceration is recommended.
西咪替丁是一种新型H2受体拮抗剂，通过静脉注射、十二指肠内给药或口服途径对18名健康男性进行了安全给药。2当用组胺或五肽胃泌素最大程度刺激胃酸分泌时，同时给予西咪替丁可显著抑制胃酸和胃蛋白酶分泌。3西咪替丁口服吸收良好，血液半衰期为2小时。4西咪替丁通过肾脏迅速排泄，排泄物质中约70%为未改变的药物。5建议对消化性溃疡患者进行西咪替丁的临床评估。
